“We have not modeled any impact from international sales in the front line RCC setting; therefore, if approved by the EMA, this could provide upside to our Cabometyx outlook. Additionally, we anticipate that under the terms of the Ipsen collaboration, Exelixis will receive a milestone payment in Q1 2018 that will exceed our estimate by approximately $30 million, but the full-year 2018 will remain unchanged, resulting from the timing of this opinion being earlier in 2018 than we had anticipated.”,” the firm’s analyst commented.
A number of other equities research analysts have also issued reports on EXEL. Zacks Investment Research upgraded Exelixis from a sell rating to a hold rating in a research report on Monday. BidaskClub lowered Exelixis from a buy rating to a hold rating in a research report on Thursday, March 1st. TheStreet lowered Exelixis from a b rating to a c+ rating in a research report on Thursday, March 15th. Oppenheimer restated a hold rating on shares of Exelixis in a research report on Thursday, January 4th. Finally, ValuEngine lowered Exelixis from a hold rating to a sell rating in a research report on Thursday, March 1st. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $34.10.
Shares of Exelixis (NASDAQ:EXEL) opened at $23.47 on Tuesday. The stock has a market capitalization of $7,149.90, a P/E ratio of 47.57, a PEG ratio of 1.40 and a beta of 1.96. Exelixis has a 52-week low of $18.03 and a 52-week high of $32.50.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Monday, February 26th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.12. The business had revenue of $120.10 million during the quarter, compared to analyst estimates of $120.25 million. Exelixis had a return on equity of 81.05% and a net margin of 34.08%. The business’s revenue was up 54.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.12 earnings per share. analysts forecast that Exelixis will post 0.54 EPS for the current fiscal year.
In related news, Director Alan M. Garber sold 15,000 shares of the stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total value of $454,500.00. Following the completion of the transaction, the director now directly owns 64,829 shares in the company, valued at $1,964,318.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lance Willsey sold 30,000 shares of the stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $23.91, for a total value of $717,300.00. Following the completion of the transaction, the director now owns 483,273 shares of the company’s stock, valued at $11,555,057.43. The disclosure for this sale can be found here. Insiders sold 120,029 shares of company stock valued at $3,158,287 over the last quarter. 5.10% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the business. Mark Sheptoff Financial Planning LLC acquired a new position in Exelixis during the third quarter worth $120,000. Sigma Planning Corp acquired a new position in Exelixis during the fourth quarter worth $208,000. American International Group Inc. acquired a new position in Exelixis during the fourth quarter worth $208,000. Klingenstein Fields & Co. LLC acquired a new position in Exelixis during the fourth quarter worth $213,000. Finally, Globeflex Capital L P acquired a new position in Exelixis during the fourth quarter worth $246,000. Institutional investors own 80.49% of the company’s stock.
WARNING: “Exelixis’ (EXEL) Buy Rating Reiterated at Cann” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2018/03/23/exelixis-exel-buy-rating-reiterated-at-cann.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.